Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Doctors are testing a new treatment for people with certain types of cancer that did not get better with other treatments. They are studying a drug called choline salicylate, which helps to reduce immune response, and combining it with a drug called selinexor. Selinexor can stop cancer cells from growing by blocking a protein called CRM1. Doctors hope to learn more about how these drugs work together to fight cancer. The trial is open for patients with non-Hodgkin or Hodgkin lymphoma, histiocytic/dendritic cell neoplasm, or multiple myeloma.
Doctors are testing a new treatment for people with certain types of cancer that did not get better with other treatments. They are studying a drug called choline salicylate, which helps to reduce immune response, and combining it with a drug called selinexor. Selinexor can stop cancer cells from growing by blocking a protein called CRM1. Doctors hope to learn more about how these drugs work together to fight cancer. The trial is open for patients with non-Hodgkin or Hodgkin lymphoma, histiocytic/dendritic cell neoplasm, or multiple myeloma.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase Ib trial evaluates the side effects and best dose of choline salicylate given together with a low dose of selinexor in treating patients with non-Hodgkin or Hodgkin lymphoma, or multiple myeloma whose prior treatment did not help their cancer (refractory) or for patients with histiocytic/dendritic cell neoplasm. Anti-inflammatory drugs, such as choline salicylate lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Selinexor may stop the growth of cancer cells by blocking a protein called CRM1 that is needed for cell growth. This trial may help doctors learn more about selinexor and choline salicylate as a treatment for with non-Hodgkin or Hodgkin lymphoma, histiocytic/dendritic cell neoplasm, multiple myeloma.
This phase Ib trial evaluates the side effects and best dose of choline salicylate given together with a low dose of selinexor in treating patients with non-Hodgkin or Hodgkin lymphoma, or multiple myeloma whose prior treatment did not help their cancer (refractory) or for patients with histiocytic/dendritic cell neoplasm. Anti-inflammatory drugs, such as choline salicylate lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Selinexor may stop the growth of cancer cells by blocking a protein called CRM1 that is needed for cell growth. This trial may help doctors learn more about selinexor and choline salicylate as a treatment for with non-Hodgkin or Hodgkin lymphoma, histiocytic/dendritic cell neoplasm, multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: